RVMD · Revolution Medicines Inc
Price
Snapshot
50 fields · last close| Market Cap | $45.20B |
| P/E | — |
| Float | 206.9M |
| Beta | 1.44 |
| Volatility | 35.9% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 68 |
| Price | 208.23 |
| Change | −1.25% |
| Prev Close | 210.87 |
| Open | 207.04 |
| Day Low | 207.04 |
| Day High | 212.06 |
| Avg Vol | 2 |
| Avg $ Vol | $442.7M |
| 52W High | 224.31 |
| 52W Low | 38.49 |
| 52W Pos | 91.3% |
| From High | −7.17% |
| From Low | +441.00% |
| Max DD 1Y | −24.95% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.74% |
| SMA 50 | +6.16% |
| SMA 200 | +56.15% |
| RSI (14) | 56.7 |
| Vol 30D | 40.5% |
| Vol 90D | 44.7% |
| 1Y Range | 38–224 |
| Daily bars | 506 |
| Perf Week | −4.65% |
| Perf Month | +6.88% |
| Perf Quarter | +35.44% |
| Perf Half Y | +111.63% |
| Perf Year | +430.22% |
| Perf YTD | +163.52% |
| Prev Day | −1.25% |
| Clavix | B- |
| Debt / Eq | 0.16 |
| Curr Ratio | 7.14 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 21 / 35 |
Clavix risk grade
regraded every trading dayRVMD grades B-, 68 of 100. Steadiest on Sector Resilience (70), most exposed on Macro Resilience (52, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 21 of 35 in Biotechnology by Clavix score.
How rough the ride is
| RVMD | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.44 | 0.50 |
| Volatilityannualized | 35.9% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −25.0% | — |
| Typical daily movemedian absolute daily change | 1.41% | — |
| Days beyond ±3%of the last 252 sessions | 5522% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RVMD | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.44 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RVMD | |
|---|---|
| 1 week | −4.6% |
| 1 month | +6.9% |
| Year to date | +163.5% |
| 1 year | +430.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RVMD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 4 Aug |
| Average score0 most bearish, 100 most bullish | 72 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 3 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| RVMD | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | RVMD | Sector spread | Median |
|---|---|---|---|
| Beta | 1.44 | 0.50 | |
| Volatility | 35.9% | 13.2% | |
| Debt / equity | 0.16 | 0.24 | |
| Current ratio | 7.14 | 3.73 |
Recent news
most recent scored articles · the chip is the article’s score · click to openThe FDA approved Revolution Medicines' drug RASONQUE (daraxonrasib) on Aug. 26, making it the first broad RAS-targeted therapy for metastatic pancreatic cancer, though the stock barely moved. No specific catalyst was identified.
Revolution Medicines signed four leases on August 27, 2026 to occupy about 672,000 square feet across four buildings in Redwood City, California, which it will use as its new headquarters. The leases start between late 2027 and late 2028, run through September 2042, and carry a combined starting base rent of roughly $2.7 million per month, with 3% annual increases and rent abatements running through January 2030.
FDA approved RASONQUE, Revolution Medicines' first oral drug that blocks cancer-driving RAS gene mutations in their active state, for metastatic pancreatic cancer that has spread. The company holds $3.9 billion in cash but expects substantial losses through 2028, with profit not projected until 2029 as global sales build.
The FDA approved Revolution Medicines' drug daraxonrasib, which will be sold under the brand name RASONQUE, for certain adults with metastatic pancreatic cancer (cancer that has spread to other parts of the body).
The FDA approved Revolution Medicines' drug daraxonrasib, sold under the brand name RASONQUE, for adults with metastatic pancreatic cancer (cancer that has spread beyond the pancreas). The drug is a once-daily pill that targets RAS proteins in their active state and works against multiple RAS mutation types.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| NTRA | Natera Inc | B- | $47.23B | — | 1.61 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C | $35.39B | 44.28 | 0.34 | Compare |
| MRNA | Moderna Inc | F | $59.43B | — | 1.22 | Compare |
| BIIB | Biogen Inc | B+ | $33.17B | 39.72 | 0.12 | Compare |
| INSM | Insmed Inc | C- | $27.66B | — | 0.82 | Compare |
| INCY | Incyte Corp | B+ | $25.95B | 16.10 | 0.78 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $86.84B | 20.26 | 0.12 | Compare |
| UTHR | United Therapeutics Corp | A- | $21.89B | 16.03 | 0.51 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.